GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Shiller PE Ratio

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Shiller PE Ratio : 20.92 (As of Jun. 23, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Shiller PE Ratio?

As of today (2024-06-23), Shanghai Kaibao Pharmaceutical Co's current share price is ¥5.44. Shanghai Kaibao Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 was ¥0.26. Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio for today is 20.92.

The historical rank and industry rank for Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

SZSE:300039' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.93   Med: 21.73   Max: 49.08
Current: 21.27

During the past years, Shanghai Kaibao Pharmaceutical Co's highest Shiller PE Ratio was 49.08. The lowest was 14.93. And the median was 21.73.

SZSE:300039's Shiller PE Ratio is ranked better than
57.12% of 534 companies
in the Drug Manufacturers industry
Industry Median: 24.175 vs SZSE:300039: 21.27

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Shanghai Kaibao Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was ¥0.085. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ¥0.26 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Shanghai Kaibao Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Shiller PE Ratio Chart

Shanghai Kaibao Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.96 - 23.28 31.04 26.08

Shanghai Kaibao Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.84 27.28 27.36 26.08 23.92

Competitive Comparison of Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio falls into.



Shanghai Kaibao Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=5.44/0.26
=20.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Kaibao Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Shanghai Kaibao Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.085/115.2271*115.2271
=0.085

Current CPI (Mar. 2024) = 115.2271.

Shanghai Kaibao Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.096 98.200 0.113
201409 0.084 98.900 0.098
201412 0.075 99.000 0.087
201503 0.084 99.900 0.097
201506 0.092 99.500 0.107
201509 0.060 100.500 0.069
201512 0.025 100.600 0.029
201603 0.078 102.200 0.088
201606 0.100 101.400 0.114
201609 0.063 102.400 0.071
201612 0.023 102.600 0.026
201703 0.085 103.200 0.095
201706 0.097 103.100 0.108
201709 0.065 104.100 0.072
201712 0.007 104.500 0.008
201803 0.093 105.300 0.102
201806 0.079 104.900 0.087
201809 0.052 106.600 0.056
201812 -0.010 106.500 -0.011
201903 0.069 107.700 0.074
201906 0.078 107.700 0.083
201909 0.053 109.800 0.056
201912 0.041 111.200 0.042
202003 0.050 112.300 0.051
202006 0.023 110.400 0.024
202009 0.028 111.700 0.029
202012 0.000 111.500 0.000
202103 0.055 112.662 0.056
202106 0.024 111.769 0.025
202109 0.032 112.215 0.033
202112 0.024 113.108 0.024
202203 0.055 114.335 0.055
202206 0.024 114.558 0.024
202209 0.034 115.339 0.034
202212 0.069 115.116 0.069
202303 0.077 115.116 0.077
202306 0.053 114.558 0.053
202309 0.058 115.339 0.058
202312 0.126 114.781 0.126
202403 0.085 115.227 0.085

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Shanghai Kaibao Pharmaceutical Co  (SZSE:300039) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Shanghai Kaibao Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Traded in Other Exchanges
N/A
Address
88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Executives
Liu Shao Yong Supervisors
Ren Li Wang Secretary Dong
Zhang Tao Executives
Mu Jing Wei Director
Li Xiu Hai Directors, executives
Zhang Lian Xin Supervisors
Han Jing Independent director
Wang Guo Ming Directors, executives
Wang Chong Bang Executives
Liu Yi Shan Director
Li Qing Wei Independent director
Mu Lai An Director
Zhu Ying Jun Executives
Chang Qing Ling Supervisors
Zhang Peng Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines